BRÈVE

sur Vogenx, Inc. (NASDAQ:VOGX)

Vogenx Set to Join Key Russell Indexes

Vogenx, Inc., a clinical-stage biopharmaceutical company focused on treating serious metabolic and gastrointestinal diseases, is set to join the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes. This inclusion is part of FTSE Russell's December 2026 semi-annual reconstitution. The membership will be effective post-market close on December 11, 2026. This marks a pivotal moment for Vogenx, occurring just months after its IPO.

James Green, CEO of Vogenx, remarked that this development will enhance the company's visibility among institutional investors as it continues the Phase 2b EMERGE study of mizagliflozin for post-bariatric hypoglycemia, a condition currently lacking FDA-approved treatments.

The Russell US Indexes are vital benchmarks for investment managers. The December 2026 reconstitution is notable as it follows FTSE Russell's shift to a semi-annual update schedule. Vogenx's inclusion reflects the company's market cap and growth potential.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Vogenx, Inc.